Daiichi Life Insurance Co. Ltd. purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 7,091 shares of the life sciences company's stock, valued at approximately $1,247,000.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in Illumina during the 2nd quarter worth $3,374,423,000. Plato Investment Management Ltd acquired a new position in Illumina in the second quarter valued at $948,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Illumina in the second quarter valued at about $30,501,000. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of Illumina in the second quarter valued at about $129,792,000. Finally, Impact Partnership Wealth LLC raised its holdings in shares of Illumina by 235.8% in the first quarter. Impact Partnership Wealth LLC now owns 11,080 shares of the life sciences company's stock valued at $1,366,000 after buying an additional 7,780 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.
Illumina Trading Up 1.7%
Shares of Illumina stock opened at $223.22 on Tuesday. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $223.97. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The company's 50-day simple moving average is $189.13 and its 200-day simple moving average is $153.14. The firm has a market cap of $33.71 billion, a price-to-earnings ratio of 41.65, a price-to-earnings-growth ratio of 3.09 and a beta of 1.44.
Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm's revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities research analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current year.
Analyst Ratings Changes
A number of equities analysts recently issued reports on ILMN shares. Leerink Partners raised their price target on Illumina from $175.00 to $210.00 and gave the stock an "outperform" rating in a report on Friday, July 17th. Sanford C. Bernstein reaffirmed a "market perform" rating and set a $215.00 price objective on shares of Illumina in a research note on Friday, July 31st. Barclays increased their price objective on Illumina from $145.00 to $160.00 and gave the stock an "underweight" rating in a research report on Friday, July 31st. Citigroup lifted their target price on Illumina from $95.00 to $113.00 and gave the company a "sell" rating in a research note on Monday, August 3rd. Finally, Zacks Research raised Illumina from a "hold" rating to a "strong-buy" rating in a report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $188.40.
Get Our Latest Report on ILMN
Insider Transactions at Illumina
In related news, Director Keith A. Meister sold 457,858 shares of Illumina stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the sale, the director directly owned 2,372,694 shares in the company, valued at $474,776,069.40. The trade was a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the transaction, the senior vice president owned 14,023 shares of the company's stock, valued at $2,685,684.96. The trade was a 6.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 2,095,958 shares of company stock valued at $401,720,974. Corporate insiders own 2.90% of the company's stock.
About Illumina
(
Free Report)
Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
See Also
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
